Biotech Analysts Fadia and Lee, along with Dr. Neha Sirohi, discuss Cogent’s SUMMIT data on bezuclastinib for indolent systemic mastocytosis presented at the American Society of Hematology (ASH) 65th Annual Meeting on an Analyst/Industry conference call to be held on December 11 at 11 am.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
- Cogent Biosciences initiated with bullish view at JPMorgan, here’s why
- Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
- Cogent Biosciences presents new preclinical data on ErbB2, PI3Kalpha programs
- Needham biotechnology analyst to hold an analyst/industry conference call